MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:

Stifel 2024 Healthcare Conference
Date: Monday, November 18th, 2024
Time: 2:25PM ET

Jefferies London Healthcare Conference
Date: Wednesday, November 20th, 2024
Time: 2:00PM GMT

A webcast and replay of Oruka's presentation will be available on the Oruka investor events website at .

About Oruka Therapeutics

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit and follow Oruka on LinkedIn.

Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com